Insilico Medicine

Insilico Medicine is an artificial intelligence company that is revolutionizing the $55 billion-dollar drug discovery industry. The company’s comprehensive drug discovery platform utilizes innovative AI solutions in transforming every step of the drug discovery and drug development process via biomarker discovery, drug development, digital medicine, and aging research. Insilico pioneered the applications of the generative adversarial networks (GANs) for identifying the next generation of novel molecular structures for the diseases with a known target and with no known targets. The company has collaborations with the world’s largest pharmaceutical companies with drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging.